Colesevelam for the management of Type 2 diabetes

Bibliography

• International Diabetes Federation. Available from: http://www.idf.org [Accessed 14 October 2008]
   Google Scholar
• American Diabetes Association. Diabetes facts and figures. 2007. Available from: http://www.diabetes.org/diabetes-statistics.jsp
   Google Scholar
• Centers for Disease Control and Prevention. National Diabetes fact sheet United States. 2007. Avialable from: http://www.diabetes.org
   Google Scholar
• Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonlyureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23:B21-9
   PubMed Web of Science ®Google Scholar
• Reasner CA. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. J Cardiovasc Pharmacol 2008;52:136-44
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil AW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards for medical care in diabetes – 2008. Diabetes Care 2008;31(Suppl 1):S12-54
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008;31:1-11
   Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul AK, Bethel MA, et al. 10-year follo-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13(Suppl 1):1-68
   PubMedGoogle Scholar
• Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27:1496-504
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289:2560-71
   PubMed Web of Science ®Google Scholar
• Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. Diabetes Care 2007;30:162-72
   PubMed Web of Science ®Google Scholar
• Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular disease: executive summary. Eur Heart J 2007;28:88-136
   PubMed Web of Science ®Google Scholar
• Nathan DM. Glycemic management of type 2 diabetes: how tight is right and how to get there. Arch Intern Med 2008;168:2064-66
   PubMed Web of Science ®Google Scholar
• Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose lowering effects of welchol study (GLOWS): a randomized, double blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007;29:74-83
   PubMed Web of Science ®Google Scholar
• Bays HE, Goldberg RB, Truitt K, et al. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin. Arch Intern Med 2008;168:1975-83
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Rosenstock J, Wang A, et al. Colesevelam HCL improves glycemic control and reduces ldl cholesterol in patients with inadequately controlled type 2 diabetes mellitus on sulfonylurea–based therapy. Diabetes Care 2008;31:1479-84
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Fonseca VA, Truitt KE, et al. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008;168:1531-40
   PubMed Web of Science ®Google Scholar
• Garg A, Gundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994;121:416-22
   PubMed Web of Science ®Google Scholar
• Yamakawa T, Takano T, Utsunomiya H, et al. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 2007;54:53-8
   PubMed Web of Science ®Google Scholar
• Parsippany, NJ. Prescribing information. WelChol (colesevelam): Sankyo Pharma, October 12; 2008
   Google Scholar
• Welchol (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes. Available from: http://www.drugs.com/newdrugs/welchol-colesevelam-hcl-receives-fda-approval-reduce-blood-glucose-adults-type-2-diabetes-810.html [Accessed October 14, 2008]
   Google Scholar
• Naarden, Netherlands. Prescribing information. Cholestagel (colesevelam), The Netherlands: Genzyme Europe BV, 12 October; 2008
   Google Scholar
• Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care 2002;25:1015-21
   PubMed Web of Science ®Google Scholar
• Pladevall M, Williams LK, Potts LA, et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004;27:2800-05
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93
   PubMed Web of Science ®Google Scholar
• Resnik HE, Foster GL, Bardsley J, et al. Achievement of American diabetes association clinical practice recommendations among US adults with diabetes 1999-2002. Diabetes Care 2006;29:531-7
   PubMed Web of Science ®Google Scholar
• Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previous diagnosed diabetes. JAMA 2004;292:335-42
   Google Scholar
• Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 2006;144:465-74
   PubMed Web of Science ®Google Scholar
• Mahley RW, Bersot TP. Drug Therapy for Hypercholesterolemia and Dyslipidemia. Eleventh edition. In: Brunton LL, Lazo JS, Parker K, et al., editors, Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2006
   Google Scholar
• Bays HE, Goldberg RB. The forgotten bile acid sequestrants: is now a good time to remember. Am J Therap 2007;14:567-80
   PubMed Web of Science ®Google Scholar
• Bays HE, Jones PH. Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease factors. Vasc Health Risk Manag 2007;3:733-42
   PubMedGoogle Scholar
• Bays HE, Dujovne C. Colesevelam HCL: a non-systemic lipid-altering drug. Expert Opin Pharmacother 2003;4:779-90
   PubMed Web of Science ®Google Scholar
• Staehls B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 2007;67:1383-92
   PubMed Web of Science ®Google Scholar
• Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J 2006;25:1419-25
   PubMed Web of Science ®Google Scholar
• Yamagata K, Daitoku H, Shimamoto Y, et al. Bile acids regulate gluconeogenic gene expression via small heterdimer partner-mediated repression of hepatocyte nuclear factor 4 and foxo1. J Biol Chem 2004;279:23158-165
   PubMed Web of Science ®Google Scholar
• Ma K, Saha PK, Chan L, et al. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006;116:1102-09
   PubMed Web of Science ®Google Scholar
• Stayrook KR, Bramlett KS, Savkur RS, et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 2005;146:984-91
   PubMed Web of Science ®Google Scholar
• Steffensen KR, Gustafsson JA. Putative metabolic effects of the liver X receptor (LXR). Diabetes 2004;53(Suppl 1):S36-42
   PubMed Web of Science ®Google Scholar
• Aldridge MA, Ito MK. Colesevelam hydrochloride: a novel bile acid-binding resin. Ann Pharmacother 2001;35:898-907
   PubMed Web of Science ®Google Scholar
• Steinmetz KL, Schonder KS. Colesevelam: potential uses for the newest bile resin. Cardiovasc Drug Rev 2005;23:15-30
   PubMedGoogle Scholar
• Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (Cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893-900
   PubMed Web of Science ®Google Scholar
• Heller DP, Burke SK, Davidson DM, et al. Absorption of colesevelam hydrochloride in health volunteers. Ann Pharmacother 2002;36:398-403
   PubMed Web of Science ®Google Scholar
• Knopp RH, Tsunehara C, Retzlaff BM, et al. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. Metabolism 2006;55:1697-703
   PubMed Web of Science ®Google Scholar
• Donovan JM, Stypinski D, Stiles MR, et al. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drug Ther 2000;14:681-90
   PubMed Web of Science ®Google Scholar
• Donovan JM, Kisicki JC, Stiles MR, et al. Effect of colesevelam on lovastatin pharmacokinetics. Ann Pharmacother 2002;36:392-7
   PubMed Web of Science ®Google Scholar
• Jones MR, Baker BA, Mathew P. Effect of colesevelam HCL on single-dose fenofibrate pharmacokinetics. Clin Pharmacokinet 2004;43:943-50
   PubMed Web of Science ®Google Scholar
• Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001;110:352-60
   PubMed Web of Science ®Google Scholar
• McKenny J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin 2005;21:1403-12
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Abby SL, Jones MR. Colesevelam hcl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. Atherosclerosis 2008 (online 5 October, 2008)
   Google Scholar
• Ferns G, Keti V, Griffin B. Investigation and management of hypertriglyceridaemia. J Clin Pathol 2008;61:1174-83
   PubMed Web of Science ®Google Scholar
• Smellie WS. Cases in primary care laboratory medicine: hypertriglyceridaemia in diabetes. BMJ 2006;333:1257-60
   PubMed Web of Science ®Google Scholar
• Fortson MR, Freedman SN, Webster PD. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol 1995;90:2134-9
   PubMed Web of Science ®Google Scholar